Wantstats
Company ProfilePremium

DIASORIN S.P.A.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
DIASORIN S.P.A. - Healthcare showcase

Year Founded & Workforce

2000

1,971 Employees

Industry

Healthcare

Services

Chemiluminescence Immunoassay (CLIA) Analyzers
D

DIASORIN S.P.A. Employee Contacts

33 verified contactsNames, job titles, seniority and locations

View Employee Contacts

DIASORIN S.P.A. Overview

Company Headquarters: Saluggia, Italy

Founded: 2000

Workforce: ~ 1,971

Company Working:

DIASORIN S.P.A. is an Italian multinational group and a global leader in the in-vitro diagnostics market. It is one of the listed companies on MTA (Mercato Telematico Azionario) in the FTSE Italia Mid Cap Index, organized and managed by Borsa Italiana S.p.A. It provides its services to hospitals, private testing laboratories of immunodiagnostics, and molecular diagnostics. It is one of the leading healthcare companies that provide services to about 4000 US hospitals and health systems and approximately 165,000 other providers and healthcare organizations. It provides services at lower costs to hospitals and other pharmaceutical industries.

Strategy

DIASORIN S.P.A. strategizes to market chemiluminescence immunoassay analyzers, products, and services to healthcare providers such as health systems and acute care hospitals. It has products that increase patients’ and users’ comfort, make laboratory work more efficient, and thus help to improve healthcare facilities worldwide, in the long term. It also invests in research and development to know the future trends and to determine the needs of its customers.

Company Snapshot

$635M

Revenue

1,971

Employees

2000

Founded

Saluggia, Italy

Headquarters

SWOT Analysis

Strengths

  • High quality products
  • Strong R&D
  • Strong presence in the domestic market

Weaknesses

  • Strong competition from international giants
  • Limited presence in developing countries

Opportunities

  • Product portfolio expansion

Threats

  • Average financial performance
  • Limited customers
  • Foreign exchange

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
July 2018Product LaunchDiaSorin and QIAGEN N.V. announced the launch of the LIAISON QuantiFERON-TB Gold Plus. It detects latent tuberculosis infection (LTBI) on LIAISON analyzer systems. This new test was developed in a partnership between DiaSorin and QIAGEN.
February 2018AgreementDIASORIN S.P.A. and the Trivitron Healthcare Group concluded a deal, according to which Trivitron Healthcare sold its minority interest (49%) held in the joint venture to the US company DiaSorin Inc., for a consideration of EUR 3.5 million.

Product Offering

  • DIASORIN S.P.A.
    • Chemiluminescence Immunoassay (CLIA) Analyzers

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 635 Mn in 2016 to USD 747 Mn in 2018.
DIASORIN S.P.A. — By Business Segment
Series (USD Mn)201620172018
Sales635711747

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →